Results 11 to 20 of about 532,092 (302)

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy [PDF]

Cochrane Database of Systematic Reviews, 2014
Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of
Martínez Zapata, Mª José, Martí Carvajal, Arturo José, Solà, Ivan, Pijoán, José I., Buil Calvo, José Antonio, Cordero Rigol, José Antonio, Evans, Jennifer R.   +6 more
openaire   +8 more sources

Anti-vascular endothelial growth factor treatment for eye diseases [PDF]

BMJ, 2012
Treatment is clearly effective but important clinical and public health implications ...
Wong, TY, Cheung, N, Lam, DSC
openaire   +6 more sources

Anti-vascular endothelial growth factor for diabetic macular oedema [PDF]

, 2014
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk of visual loss in DMO, or clinically significant macular oedema (CSMO), vision is rarely improved.
VIRGILI, GIANNI, Parravano M, Menchini F, Brunetti M.   +3 more
openaire   +5 more sources

Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis [PDF]

Health Technology Assessment
Background Diabetic retinopathy is a major cause of sight loss in people with diabetes. The most severe form, proliferative diabetic retinopathy, carries a high risk of vision loss, vitreous haemorrhage, macular oedema and other harms.
Mark Simmonds, Alexis Llewellyn, Ruth Walker, Helen Fulbright, Matthew Walton, Rob Hodgson, Laura Bojke, Lesley Stewart, Sofia Dias, Thomas Rush, John G Lawrenson, Tunde Peto, David Steel   +12 more
doaj   +2 more sources

Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis [PDF]

Health Technology Assessment
Background Diabetic retinopathy is a major cause of sight loss in people with diabetes, with a high risk of macular oedema, vitreous haemorrhage or other complications.
Mark Simmonds, Matthew Walton, Rob Hodgson, Alexis Llewellyn, Ruth Walker, Helen Fulbright, Laura Bojke, Lesley Stewart, Sofia Dias, Thomas Rush, John Lawrenson, Tunde Peto, David Steel   +12 more
doaj   +2 more sources

Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis [PDF]

Health Technology Assessment
Background Proliferative diabetic retinopathy is a major cause of sight loss in people with diabetes, with a high risk of vitreous haemorrhage, tractional retinal detachment and other complications.
Mark Simmonds, Alexis Llewellyn, Ruth Walker, Helen Fulbright, Matthew Walton, Rob Hodgson, Laura Bojke, Lesley Stewart, Sofia Dias, Thomas Rush, João Pereira Figueira, Sobha Sivaprasad, John G Lawrenson, Tunde Peto, David Steel   +14 more
doaj   +2 more sources

Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report

Journal of Medical Case Reports, 2021
Background Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat macular diseases, including diabetic macular edema.
Miwako Yoshimoto, Nobuhiko Takeda, Takayuki Yoshimoto, Shun Matsumoto   +3 more
doaj   +1 more source

In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis [PDF]

, 2014
Methodology: We have utilized a rational in silico-based approach to demonstrate the design and study of a novel compound that acts as a dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1).
AM Latham, Antony M. Latham, B Apsel, Colin W. G. Fishwick, D Santamaria, Domenico Ribatti, E Schonbrunn, EA Murphy, G Bergers, G Draetta, Gareth W. Fearnley, GI Evan, GJ Howell, GW Fearnley, H Haddad, H Huynh, I Zachary, J Galon, J Kankanala, J Lee, J Pines, Jayakanth Kankanala, JC Tille, JJ Tung, JM Ebos, JW Schmidberger, K Boda, KM Malinda, M Doree, M Mohammadi, MA Ali, MA Branca, Mark T. Kearney, Matthew C. Gage, MP Jacobson, MS Squires, N Ferrara, O Timofeev, P Carmeliet, P Carmeliet, PA Harris, PG Wyatt, Q Wang, R Morphy, RA Friesner, RA Friesner, S Emanuel, S Huang, S Koch, S Koch, S Ponnambalam, Shervanthi Homer-Vanniasinkam, Sreenivasan Ponnambalam, Stephen B. Wheatcroft, T Anastassiadis, T Bashir, TA Halgren, TA Potapova, V Knights, VE Neubrand, ZW Cai   +60 more
core   +6 more sources

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma [PDF]

Journal of Clinical Oncology, 2015
Treatment of glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains a significant unmet need in oncology. Historically, cytotoxic treatments provided little durable benefit, and tumors recurred within several months.
Lu-Emerson, Christine, Duda, Dan G, Emblem, Kyrre E, Taylor, Jennie W, Gerstner, Elizabeth R, Loeffler, Jay S, Batchelor, Tracy T, Jain, Rakesh K   +7 more
openaire   +4 more sources

Ropivacaine vs tetracaine in topical anesthesia for intravitreal injection [PDF]

, 2015
Aim: The object of the study was to evaluate the long term efficacy and safety of ropivacaine 0,5% vs tetracaine 0,5% for topical anesthesia in intravitreal injection of dexamethasone in patients with diabetic macular edema (DME) and anti-vascular ...
COLLINI, Saul, PACELLA, Elena, PACELLA, FERNANDA, SALDUCCI, Mauro, SMALDONE, GIANPAOLO, Troisi, Fabiana, TURCHETTI, PAOLO   +6 more
core   +1 more source